Classification of amyloid on fixed tissue sections for routine use by validated immunohistochemistry
R. Linke
DOI: https://doi.org/10.3109/13506129.2011.574354024
2011-06-01
Abstract:For therapeutical considerations, every amyloidosis needs to be classified by identifying the chemical nature of the amyloidogenic protein(s) out of at least 27 that come in question, since each protein causes a different disease. Classifying of amyloid can be done directly by amino acid sequencing of the isolated protein and more indirectly on formalin-fixed tissue sections by quantitative peptide estimation using mass spectrometry (MS) or by immunohistochemical means. For the latter, we prepared special antibodies. Of 119 prototype amyloids, including 14 different classes, the correct amyloid type was obtained in 100% and in 97.9% of 581 unknown samples, both in a blinded fashion. Similar results were obtained independently in other laboratories using our antibodies. These results are independent of any clinical pre-knowledge. This improved amyloid typing method is reliable, very fast, easy, and affordable for all institutes competent in performing immunohistochemistry. Finally, the first blinded international comparison between this validated immunohistochemistry and MS has also been concluded. Introduction: In recent decades, the classification of amyloidosis has received increasing attention since more and more different amyloid diseases have been discovered, which has ultimately resulted in a list exceeding 27 different amyloid classes [1]. These amyloid classes are determined by the analysis of the chemical nature of the amyloidogenic protein within the amyloid complex. In addition, each of the different amyloid classes can display further clinical and genetic variants, thus resulting in additional diversity, which amounts to more than 500 different individual amyloid diseases. This plethora of entities needs to be classified and clinically differentiated, in particular since some efficient therapies have been reported. This amyloid complex as seen in tissue sections is not represented by a single protein, but it contains a host of different proteins. In order to find out the amyloidogenic protein(s) within the amyloid complex, one requires a method that serves this purpose reliably. The classification (or typing) of amyloid can best be achieved directly by amino acid sequencing of the chromatographically purified amyloidogenic protein or, more indirectly, by a quantitative peptide estimation using either mass spectrometry (MS) [2,3] or by immunohistochemical means [4–8]. The latter two methods make use of the whole and unseparated amyloid complex as is found to be present in formalin-fixed paraffin sections. In this report, results of amyloid typing have been presented using validated immunohistochemistry on formalin-fixed paraffin tissue sections. An in-depthreview of this procedure has been submitted [9]. Finally, since the first international comparison between MS and validated immunohistochemistry has been concluded in 2009, a short comment concerning some of its results with respect to the amyloid typing procedure presented here will be added. Material and methods: Tissue samples and the diagnosis of amyloid: Amyloid-containing tissue samples were submitted to us by physicians for classifying the amyloid or submitted for scientific reasons. The tissue was either frozen, formalin-fixed, or it arrived in the form of a paraffin section on glass slides. All amyloid samples were processed to be analyzed in the form of paraffin sections. Some amyloidogenic proteins were also isolated and identified by amino acid sequencing or immunochemically, such as by Western blotting. In case of heredity, the amyloidotic protein was confirmed by genetic analysis. Tissue samples whose amyloid was confirmed structurally have been used as amyloid prototypes. Amyloid was identified using the conventional Congo red staining method in its abbreviated variety [5]. The diagnosis of amyloid was made microscopically by the recognition of the affinity by Congo red affinity and by the pathognomonic green birefringence. When minute amounts of amyloid were present, Congo red fluorescence was employed [5]. Standardization of amyloid antibodies on amyloid prototypes and application to routine use: Antibodies were prepared against amyloidogenic proteins in rabbits and mice (monoclonals). They were selected according to their performance first on prototype amyloid tissues and later also on unknown samples submitted to us for routine amyloid typing. This procedure of selecting the antibodies against the most frequent amyloids lasted up to approximately 1995, but even better antibodies against the common amyloids and against newly emerging amyloids have been produced since then and are still being produced. In addition, this emerging set of antibodies has been sent to all physicians who asked for them either on the basis of cooperation or simply for amyloid typing in patients until approximately 2002. Illustrating their apparent usefulness, we delivered approximately 1.8 million tests of various antibodies to 64 different institutions worldwide, according to our records. Classification of the different amyloid diseases: A list of our standard antibodies is shown in Table I. 67